HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research Feb 24, 2022 08:00AM
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch Nov 11, 2021 07:59AM
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch Nov 3, 2021 07:30AM
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch Nov 3, 2021 07:00AM
PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021 Sep 7, 2021 05:37PM


Apr 27, 2021 07:00AM PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™
Apr 12, 2021 06:00AM CEO Presenting on the Emerging Growth Conference on April 14; Register now
Feb 17, 2021 09:01AM PharmaTher Announces Sale of Psilocybin Program
Dec 21, 2020 07:59AM PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics
Dec 21, 2020 07:59AM Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program
Nov 24, 2020 11:09AM PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs
Nov 18, 2020 07:00AM Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics
Nov 18, 2020 07:00AM PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform
Jul 16, 2018 08:05AM WeedMD Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
Jun 13, 2018 07:00AM Revive Therapeutics and WeedMD Sign Medical Cannabis R&D Supply and Collaboration Agreements
Jun 13, 2018 07:00AM WeedMD and Revive Therapeutics Sign Medical Cannabis R&D Supply and Collaboration Agreements
Mar 28, 2018 04:30PM Revive Therapeutics Retained Mi3 Communications for Investor Relations Services